Volume 24 includes six contributions, the author and paper index of volumes 1-24 and the key-word index. Since volume 23 included an index for volumes 16-23 the reader has the possibility to use these monographs as an encyclopedia and is in the position to find references to almost all fields of drug research. The editor hopes that the articles of the present volume will prove interesting and useful to many scientists and would be grateful to receive suggestions and opinions from readers, as in the past case over the 20 years in which this series of monographs has existed. In this respect, thanks are due to all colleagues who have provided helpful criticism of past volumes, thereby helping the editor in his work. Dr. A. Naf again has assisted the editor and has carefully reviewed all manuscripts, formulae and references, and has corrected the proofs. Thanks are due to him for this immense work. At the same time, the editor would like to thank the publishers and printers, Verlag Birkhliu ser, in particular Messrs. Th. Birkhliuser and C. Einsele, for the excellent cooperation and the work they have accomplished.

Contents: V. Zingel, C. Leschke and W. Schunack: Developments in research on histamine (H1) receptor agonists / P.D. Hoeprich: Antifungal chemotherapy / G. de Stevens: The diversity of heterocyclic compounds and their biological activities / R.M. Schultz: Newer antifolate compounds in cancer therapy / P.K. Mehrotra, S. Batra and A.P. Bhadun: Non-steroidal agents for regulation of the menstrual cycle / A.K. Saxena and M. Saxena: Developments in anti-convulsant drugs

Volume 42 of "Progress in Drug Research" contains seven reviews and the various indexes which facilitate its use and establish the con nection with the previous volumes. The articles in this volume deal with organization and management of drug research; luteinizing hor mone regulators; natural products as anticancer agents; flavonoids and their pharmacological activity; serenics in the control of mental disturbances; Transfer Factor and its application and with Transfer Factor in malignancy. In the 34 years that "Progress in Drug Research" has existed, the Edi tor has enjoyed the valuable help and advice of many colleagues. Readers, the authors of the reviews, and last but not least, the review ers have all contributed greatly to the success of this series. Although the comments received so far have generally been favorable, it is nevertheless necessary to analyze and to reassess the current position and the future direction of such a review series. So far, it has been the Editors intention to help disseminate informa tion on the vast domain of drug research, and to provide the reader with a tool with which to keep abreast of the latest developments and trends. The reviews in PDR are useful to the non-specialists, who can obtain an overview of a particular field of drug research in a rela tively short time.